View Financial HealthPAO Group 배당 및 자사주 매입배당 기준 점검 0/6PAO Group 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Mar 20PAO Group, Inc. Announces Resignation of James Schramm as Chief Executive Officer, Effective March 18, 2026PAO Group, Inc. announced that James Schramm has resigned as Chief Executive Officer and that the Purchase and Sale Agreement dated July 21, 2025 has been formally rescinded, effective March 18, 2026, pursuant to a mutual agreement between Mr. Schramm and PAO Group, Inc. Under the terms of the rescission, Law90, LLC will be returned to James Schramm, and Mr. Schramm will return 3,510,000 Preferred C shares of PAO Group, Inc. to James C. DiPrima. Mr. Schramm intends to convey Law90, LLC to Green Stream Holdings, Inc. (“GSFI”). Law90, LLC is a Company which refers cases to attorneys which are members of Law90, LLC. The Company remains focused on advancing its strategic initiatives, strengthening operational continuity, and positioning PAOG for long-term growth. Additional updates regarding leadership and corporate developments will be provided as appropriate.공시 • Jun 22PAO Group, Inc. Confirms CBD Nutraceuticals Business Development Update to Include ALKM, USMJ and PURA Highlights Scheduled on June 23, 2021PAO Group, Inc. confirmed CBD Nutraceuticals Business Development Update on June 23, 2021. PAOG plans to launch a CBD Nutraceuticals line of products expected to generate revenue this year, in 2021, is on track. The company also continues in the long-term CBD pharmaceutical. The 2020 CBD Nutraceuticals Market had an estimated value of $5.2 Billion, and it is expected to reach $16.4 Billion by 2027. PAOG is working on the development of a CBD pharmaceutical product under the name RespRx, for the treatment of Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT." PAOG plans to develop and distribute its CBD nutraceuticals with Alkame Holdings, Inc. (OTC Pink: ALKM) as a copacker and North American Cannabis Holdings, Inc. (OTC Pink: USMJ) as a distributor. The update on Wednesday will include highlights on ALKM and USMJ roles in PAOG’s CBD Nutraceuticals Business Development. The update will also include an update on the intended distribution of PAOG stock to PURA (OTC Pink: PURA) shareholders in conjunction with PAOG’s acquisition of PURA’s cannabis cultivation operation.공시 • Jun 18PAOG Plans to Launch CBD Nutraceuticals Line of ProductsPAO Group, Inc. confirmed the company’s plan to launch a CBD Nutraceuticals line of products expected to generate revenue this year, in 2021, is on track. The company also continues in the long-term CBD pharmaceutical. Next week, on June 23, management will release an update on the company’s CBD Nutraceuticals development initiative to include new developments expected to expand company’s overall market opportunity. The company is working on the development of a CBD pharmaceutical product under the name RespRx, for the treatment of Chronic Obstructive Pulmonary Disorder derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.공시 • May 08Pao Group, Inc. Releases Preview of the Company's Plan to Launch CBD Nutraceuticals Line of ProductsPAO Group, Inc. released preview of the company's plan to launch CBD Nutraceuticals line of products. PAOG's CBD Nutraceuticals are expected to generate revenue this year, in 2021, while the company continues with its long-term CBD pharmaceutical developments. PAOG is working on the development of a CBD pharmaceutical product under the name RespRx, for the treatment of Chronic Obstructive Pulmonary Disorder derived from a patented cannabis extraction method. Starting in the fourth quarter of 2021, PAOG plans to begin the introduction of three CBD Nutraceuticals. The first CBD Nutraceutical under development will sell under the name CBD RELAX-RX targeting the anxiety and depression treatment market anticipated to reach a value of $18 billion by 2025. The second CBD Nutraceutical under development will be derived from PAOG's ongoing COPD research targeting the COPD treatment market separately from the pharmaceutical market also targeting COPD treatment. The third CBD Nutraceutical is being developed in partnership with the EVERx CBD Sports Water Brand owned by Puration, Inc. and will target the sports nutrition market. PAOG plans to develop and distribute its CBD nutraceuticals with Alkame Holdings, Inc. as a copacker and North American Cannabis Holdings, Inc. as a distributor.공시 • Oct 16PAO Expects to Finalize Cro Engagement for Cannabis Drug Within Next Two WeeksPAO Group, Inc. published a progress update on the company's ongoing initiative to advance an investigational New Drug application (IND) with the Food and Drug Administration (FDA). PAOG anticipates entering into an agreement with a contract research organization (CRO) within the next two weeks. The CRO engagement will be a major breakthrough in advancing PAOG's RespRx treatment for Chronic Obstructive Pulmonary Disease (COPD) toward FDA approval. In an initial scientific evaluation as a treatment for COPD, RespRx has demonstrated effecting significant increases in respiration rate, tidal volume and inspiratory air flow rate. Overall data from the evaluation demonstrated that RespRx can significantly improve inspiratory lung functions in instances of moderate pulmonary fibrosis. In conjunction with PAOG's acquisition of RespRx, the company also recently acquired a hemp cultivation business from Puration, Inc. to develop a proprietary cultivar to support PAOG's cannabis pharmaceutical treatment objectives. PAOG's Farmersville cultivar development operation will include a lab and an environmentally controlled indoor growing facility. PAOG is working with current cultivars to evolve and produce an ideal plant with full spectrum, high CBD yields to support ongoing RespRx development and to support future CBD pharmaceutical developments. PAOG is exploring opportunities to engage with university research in partnership with its hemp cultivar development initiative.공시 • Jul 18PAO Group, Inc. (OTCPK:PAOG) agreed to acquire NCM Biotech from Kali, Inc. (OTCPK:KALY).PAO Group, Inc. (OTCPK:PAOG) agreed to acquire NCM Biotech from Kali, Inc. (OTCPK:KALY) on July 16, 2020. PAO Group agreed to acquire NCM Biotech in exchange for common shares of PAOG that will in turn be issued to KALY shareholders in a dividend distribution. The NCM Biotech sale marks an exit from the cannabis industry for KALY. The transaction is expected to be complete by the end of July 2020.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 PAOG 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: PAOG 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장PAO Group 배당 수익률 vs 시장PAOG의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (PAOG)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.2%업계 평균 (Pharmaceuticals)2.0%분석가 예측 (PAOG) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 PAOG 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 PAOG 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 PAOG 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: PAOG 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/09 16:13종가2026/06/09 00:00수익N/A연간 수익N/A데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스PAO Group, Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Mar 20PAO Group, Inc. Announces Resignation of James Schramm as Chief Executive Officer, Effective March 18, 2026PAO Group, Inc. announced that James Schramm has resigned as Chief Executive Officer and that the Purchase and Sale Agreement dated July 21, 2025 has been formally rescinded, effective March 18, 2026, pursuant to a mutual agreement between Mr. Schramm and PAO Group, Inc. Under the terms of the rescission, Law90, LLC will be returned to James Schramm, and Mr. Schramm will return 3,510,000 Preferred C shares of PAO Group, Inc. to James C. DiPrima. Mr. Schramm intends to convey Law90, LLC to Green Stream Holdings, Inc. (“GSFI”). Law90, LLC is a Company which refers cases to attorneys which are members of Law90, LLC. The Company remains focused on advancing its strategic initiatives, strengthening operational continuity, and positioning PAOG for long-term growth. Additional updates regarding leadership and corporate developments will be provided as appropriate.
공시 • Jun 22PAO Group, Inc. Confirms CBD Nutraceuticals Business Development Update to Include ALKM, USMJ and PURA Highlights Scheduled on June 23, 2021PAO Group, Inc. confirmed CBD Nutraceuticals Business Development Update on June 23, 2021. PAOG plans to launch a CBD Nutraceuticals line of products expected to generate revenue this year, in 2021, is on track. The company also continues in the long-term CBD pharmaceutical. The 2020 CBD Nutraceuticals Market had an estimated value of $5.2 Billion, and it is expected to reach $16.4 Billion by 2027. PAOG is working on the development of a CBD pharmaceutical product under the name RespRx, for the treatment of Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT." PAOG plans to develop and distribute its CBD nutraceuticals with Alkame Holdings, Inc. (OTC Pink: ALKM) as a copacker and North American Cannabis Holdings, Inc. (OTC Pink: USMJ) as a distributor. The update on Wednesday will include highlights on ALKM and USMJ roles in PAOG’s CBD Nutraceuticals Business Development. The update will also include an update on the intended distribution of PAOG stock to PURA (OTC Pink: PURA) shareholders in conjunction with PAOG’s acquisition of PURA’s cannabis cultivation operation.
공시 • Jun 18PAOG Plans to Launch CBD Nutraceuticals Line of ProductsPAO Group, Inc. confirmed the company’s plan to launch a CBD Nutraceuticals line of products expected to generate revenue this year, in 2021, is on track. The company also continues in the long-term CBD pharmaceutical. Next week, on June 23, management will release an update on the company’s CBD Nutraceuticals development initiative to include new developments expected to expand company’s overall market opportunity. The company is working on the development of a CBD pharmaceutical product under the name RespRx, for the treatment of Chronic Obstructive Pulmonary Disorder derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.
공시 • May 08Pao Group, Inc. Releases Preview of the Company's Plan to Launch CBD Nutraceuticals Line of ProductsPAO Group, Inc. released preview of the company's plan to launch CBD Nutraceuticals line of products. PAOG's CBD Nutraceuticals are expected to generate revenue this year, in 2021, while the company continues with its long-term CBD pharmaceutical developments. PAOG is working on the development of a CBD pharmaceutical product under the name RespRx, for the treatment of Chronic Obstructive Pulmonary Disorder derived from a patented cannabis extraction method. Starting in the fourth quarter of 2021, PAOG plans to begin the introduction of three CBD Nutraceuticals. The first CBD Nutraceutical under development will sell under the name CBD RELAX-RX targeting the anxiety and depression treatment market anticipated to reach a value of $18 billion by 2025. The second CBD Nutraceutical under development will be derived from PAOG's ongoing COPD research targeting the COPD treatment market separately from the pharmaceutical market also targeting COPD treatment. The third CBD Nutraceutical is being developed in partnership with the EVERx CBD Sports Water Brand owned by Puration, Inc. and will target the sports nutrition market. PAOG plans to develop and distribute its CBD nutraceuticals with Alkame Holdings, Inc. as a copacker and North American Cannabis Holdings, Inc. as a distributor.
공시 • Oct 16PAO Expects to Finalize Cro Engagement for Cannabis Drug Within Next Two WeeksPAO Group, Inc. published a progress update on the company's ongoing initiative to advance an investigational New Drug application (IND) with the Food and Drug Administration (FDA). PAOG anticipates entering into an agreement with a contract research organization (CRO) within the next two weeks. The CRO engagement will be a major breakthrough in advancing PAOG's RespRx treatment for Chronic Obstructive Pulmonary Disease (COPD) toward FDA approval. In an initial scientific evaluation as a treatment for COPD, RespRx has demonstrated effecting significant increases in respiration rate, tidal volume and inspiratory air flow rate. Overall data from the evaluation demonstrated that RespRx can significantly improve inspiratory lung functions in instances of moderate pulmonary fibrosis. In conjunction with PAOG's acquisition of RespRx, the company also recently acquired a hemp cultivation business from Puration, Inc. to develop a proprietary cultivar to support PAOG's cannabis pharmaceutical treatment objectives. PAOG's Farmersville cultivar development operation will include a lab and an environmentally controlled indoor growing facility. PAOG is working with current cultivars to evolve and produce an ideal plant with full spectrum, high CBD yields to support ongoing RespRx development and to support future CBD pharmaceutical developments. PAOG is exploring opportunities to engage with university research in partnership with its hemp cultivar development initiative.
공시 • Jul 18PAO Group, Inc. (OTCPK:PAOG) agreed to acquire NCM Biotech from Kali, Inc. (OTCPK:KALY).PAO Group, Inc. (OTCPK:PAOG) agreed to acquire NCM Biotech from Kali, Inc. (OTCPK:KALY) on July 16, 2020. PAO Group agreed to acquire NCM Biotech in exchange for common shares of PAOG that will in turn be issued to KALY shareholders in a dividend distribution. The NCM Biotech sale marks an exit from the cannabis industry for KALY. The transaction is expected to be complete by the end of July 2020.